Diabetes Market Analysis, Size, Trends | 2019-2025 | MedSuite
- Year: 2019
- Scope: 2015-2025
- Region: Europe, United States
- Pages: 754
- Published Date: 06/04/2019
- Type: MedSuite
Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.
- Insulin Syringes – MedCore – The insulin syringes market analysis consists of safety and conventional syringe segments.
- Insulin Pumps – MedCore – The insulin pump market is segmented into the durable pump, patch pump, and simple pump markets.
- Insulin – MedCore – The insulin market analysis is further segmented into long-lasting, rapid-acting, human, premixed, and ultra-long-lasting markets.
- Insulin Pen – MedCore – The insulin pen market consists of needle pen and reusable pen market segments.
- Blood Glucose Meters – MedCore – The market for blood glucose meters is comprised of professional and personal markets.
- Blood Glucose Test Strips – MedCore – The market for blood glucose test strips is segmented into personal and professional test strip markets.
- Lancet and Lancing Devices – MedCore – The lancet and lancing devices market consists of professional and personal device market segments.
- Continuous Glucose Monitoring – MedCore – The market for continuous glucose monitoring is also comprised of professional and personal device segments.
- Diabetes Monitoring, Treatment and Drug Delivery – MedPro – Discusses the number of procedures performed in the diabetes market.
Market Value and Industry Trends
By 2019, the U.S. diabetes monitoring, treatment, and drug delivery market was valued at $15.7 billion while the European market was valued at €6.8 billion. The US market is expected to grow by 0.6% and reach $16.4 billion by 2025. However, the European diabetes market is expected to experience a higher growth of 4.3% and reach €9 billion by 2025.
The fastest-growing segment in the U.S. diabetes market is the FGM market, which has increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM. Abbott received FDA approval for FreeStyle® Libre and for FreeStyle® Libre 14 Day. The FGM market has experienced significant growth in international markets since it was first commercially launched in Europe almost ten years ago. Growth in the U.S. market is expected to follow a similar trend, primarily attributed to an expanding installed base of FGM users.
In the EU diabetes market, pricing pressure and price erosion are common occurrences, as new competitors enter the blood glucose monitoring market and pen needle markets, with low-price strategies and products. The presence of these new competitors puts downward pressure on the average selling price and has caused traditional market leaders to introduce low-priced products of their own, in order to counteract the increased competition in the segment. Tender negotiations and budgetary pressures on national healthcare expenditure also contribute to the decline in prices and have resulted in market value contractions in certain regions. It is expected that the trend of pricing pressure will continue throughout the forecast period, limiting the value of the blood glucose monitoring and the pen needle markets.
In both the U.S. and EU markets, the vast majority of the overall market share was held by insulin manufacturers, Novo Nordisk, Eli Lilly, and Sanofi. In the US, Novo Nordisk held the leading position in the ultra-long-acting insulin rapid-acting insulin markets and the second-leading position in the long-acting insulin, premixed insulin, and human insulin markets. In Europe, on the other hand, Novo Nordisk held the leading position in the rapid-acting insulin and premixed insulin markets and the second-leading position in the long-acting insulin, ultra-long-acting insulin, and human insulin markets.
In the US, other notable competitors in the market include Abbott, Becton Dickinson, and LifeScan. Although it has shifted focus to the FGM market, Abbott still maintained a notable position in the blood glucose monitoring (BGM) segments. Becton Dickinson maintained its dominant position in the insulin pen and insulin syringe markets. LifeScan also maintained its leading position in the blood glucose test strip and lancet markets.
In Europe, other leading notable competitors in the market include Roche, Abbott, and Becton Dickinson. Roche continued to hold the leading position in the blood glucose meter, blood glucose test strip and lancet markets, as well as the second-leading position in the insulin pump market. Abbott continued to benefit from its monopolistic position in the FGM market. Becton Dickinson remained dominant in the insulin pen needle and insulin syringe markets.
Diabetes Statistics and Disease Overview
Obesity is considered by leading health organizations, such as the Centers for Disease Control (CDC), as a prevalent disease both globally and in the United States. According to the CDC, there has been a considerable increase in the incidence of obesity in the U.S. over the past 20 years.
The latest data on obesity in the U.S. shows that today, nearly 38% of adults at the age of 20 years and over are obese. For adolescents at the age of 12 to 19 years, children at the age of 6 to 11 years, and children at the age of 2 to 5 years, the obesity rate is considerably lower at approximately 21%, 17%, and 9%, respectively. On the bright side, this rate has plateaued in the last few years. Being obese makes it difficult for cells to respond to insulin, thus the body reacts by releasing more insulin. Therefore, obesity has been seen as one of the main reasons behind the advance of type 2 diabetes among Americans.
Detailed Market Segmentation
Data Types Included
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2025, and Historical Data
- Market Drivers & Limiters for Each Diabetes Device Segment
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Disease Overviews and Demographic Information
- Related Press Releases from Top Competitors
Report Regional Coverage
Throughout this research series, iData has covered several countries in great detail. Each country may be purchased as a stand-alone report, tailoring the data to your needs. The covered countries are:
- United States
- Benelux (Belgium, Netherlands, and Luxembourg)
- Scandinavia (Denmark, Finland, Norway, and Sweden)
Recent Market Developments
May 2019 – LifeScan enters into an agreement with Sanvita Medical to market and distribute CGM devices
January 2019 – Ascensia Diabetes Care announces global partnership with POCTech to distribute and co-develop CGM systems
January 2019 – CGM pledge for pregnant woman with type 1 diabetes outlined in NHS plan
November 2018 – Dexcom and Verily amend collaboration and license agreement
November 2018 – NHS to provide increased access to FGM for type 1 diabetes patients
DON’T SEE THE SEGMENT OR DATA YOU NEED?
Feel free to contact us or send a request by pressing one of the buttons below.
TABLE OF CONTENTSLIST OF FIGURES VII LIST OF CHARTS XI EXECUTIVE SUMMARY 1
U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEWCOMPETITIVE ANALYSIS 4 MARKET TRENDS 7 MARKET DEVELOPMENTS 9 PROCEDURE NUMBERS 10 PROCEDURE CODES INVESTIGATED 11 MARKETS INCLUDED 12 KEY REPORT UPDATES 14 VERSION HISTORY 14
RESEARCH METHODOLOGY1.1 RESEARCH SCOPE 15 1.2 IDATA’S 9-STEP METHODOLOGY 15 Step 1: Project Initiation & Team Selection 15 Step 2: Prepare Data Systems and Perform Secondary Research 17 Step 3: Preparation for Interviews & Questionnaire Design 18 Step 4: Performing Primary Research 19 Step 5: Research Analysis: Establishing Baseline Estimates 21 Step 6: Market Forecast and Analysis 22 Step 7: Identify Strategic Opportunities 24 Step 8: Final Review and Market Release 25 Step 9: Customer Feedback and Market Monitoring 26
DISEASE OVERVIEW2.1 INTRODUCTION 27 2.1.1 Types of Diabetes 27 2.1.2 Diabetes Complications 29 2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes 31 2.1.4 Signs and Symptoms 32 2.1.5 Diabetes Monitoring 34 2.1.6 Treatment 36 2.1.7 Drug Delivery Systems 37
U.S. DIABETES MONITORING, TREATMENT AND DRUG DELIVERY MARKET OVERVIEW3.1 MARKET OVERVIEW 39 3.2 TREND ANALYSIS 45 3.3 DRIVERS AND LIMITERS 49 3.3.1 Market Drivers 49 3.3.2 Market Limiters 50 3.4 COMPETITIVE MARKET SHARE ANALYSIS 53 3.5 MERGERS AND ACQUISITIONS 57
BLOOD GLUCOSE METER MARKET4.1 INTRODUCTION 58 4.2 MARKET OVERVIEW 60 4.3 MARKET ANALYSIS AND FORECAST 64 4.3.1 Total Blood Glucose Meter Market 64 126.96.36.199 Personal Blood Glucose Meter Market 66 188.8.131.52 Professional Blood Glucose Meter Market 69 4.4 DRIVERS AND LIMITERS 71 4.4.1 Market Drivers 71 4.4.2 Market Limiters 71v4.5 COMPETITIVE MARKET SHARE ANALYSIS 74
BLOOD GLUCOSE TEST STRIP MARKET5.1 INTRODUCTION 78 5.2 MARKET OVERVIEW 79 5.3 MARKET ANALYSIS AND FORECAST 83 5.3.1 Total Blood Glucose Test Strip Market 83 5.3.2 Total Personal Blood Glucose Test Strip Market 85 184.108.40.206 Medicare/Medicaid Blood Glucose Test Strip Market 89 220.127.116.11 Managed Care Blood Glucose Test Strip Market 91 18.104.22.168 Cash Blood Glucose Test Strip Market 93 5.3.3 Professional Blood Glucose Test Strip Market 95 5.4 DRIVERS AND LIMITERS 97 5.4.1 Market Drivers 97 5.4.2 Market Limiters 98 5.5 COMPETITIVE MARKET SHARE ANALYSIS 100
LANCET AND LANCING DEVICE MARKET6.1 INTRODUCTION 104 6.2 MARKET OVERVIEW 106 6.3 MARKET ANALYSIS AND FORECAST 109 6.3.1 Total Lancet and Lancing Device Market 109 22.214.171.124 Personal Lancet and Lancing Device Market 111 126.96.36.199 Professional Lancet and Lancing Device Market 114 6.4 DRIVERS AND LIMITERS 116 6.4.1 Market Drivers 116 6.4.2 Market Limiters 116 6.5 COMPETITIVE MARKET SHARE ANALYSIS 119
CONTINUOUS GLUCOSE MONITORING MARKET7.1 INTRODUCTION 123 7.2 MARKET OVERVIEW 125 7.3 MARKET ANALYSIS AND FORECAST 129 7.3.1 Total Personal Continuous Glucose Monitoring Market 129 188.8.131.52 Personal Continuous Glucose Monitoring Receiver Market 133 184.108.40.206 Personal Continuous Glucose Monitoring Transmitter Market 135 220.127.116.11 Personal Continuous Glucose Monitoring Sensor Market 138 7.3.2 Total Professional Continuous Glucose Monitoring Market 140 18.104.22.168 Professional Continuous Glucose Monitoring System Market 144 22.214.171.124 Professional Continuous Glucose Monitoring Transmitter Market 146 126.96.36.199 Professional Continuous Glucose Monitoring Sensor Market 148 7.3.3 Emerging Markets: Non-Invasive CGM 150 7.4 DRIVERS AND LIMITERS 151 7.4.1 Market Drivers 151 7.4.2 Market Limiters 153 7.5 COMPETITIVE MARKET SHARE ANALYSIS 155
INSULIN MARKET8.1 INTRODUCTION 159 8.1.1 Insulin Types 159 188.8.131.52 Rapid-Acting Insulin Analogs 159 184.108.40.206 Regular Human Insulin 160 220.127.116.11 Intermediate-Acting Human Insulin 160 18.104.22.168 Long-Acting Insulin Analogs 160 22.214.171.124 Ultra-Long-Acting Insulin Analogs 160 126.96.36.199 Premixed Insulin 160 8.2 MARKET OVERVIEW 162 8.3 MARKET ANALYSIS AND FORECAST 166 8.3.1 Total Insulin Market 166 188.8.131.52 Long-Acting Insulin Market 169 184.108.40.206 Rapid-Acting Insulin Market 172 220.127.116.11 Premixed Insulin Market 175 18.104.22.168 Human Insulin Market 177 8.4 DRIVERS AND LIMITERS 179 8.4.1 Market Drivers 179 8.4.2 Market Limiters 180 8.5 COMPETITIVE MARKET SHARE ANALYSIS 182
INSULIN PEN MARKET9.1 INTRODUCTION 185 9.2 MARKET OVERVIEW 187 9.3 MARKET ANALYSIS AND FORECAST 191 9.3.1 Prefilled Insulin Pen Market 191 9.3.2 Insulin Pen Cartridge Market 194 9.3.3 Reusable Insulin Pen Market 197 9.3.4 Total Insulin Pen Needle Market 200 22.214.171.124 Conventional Insulin Pen Needle Market 203 126.96.36.199 Safety Insulin Pen Needle Market 206 9.4 DRIVERS AND LIMITERS 208 9.4.1 Market Drivers 208 9.4.2 Market Limiters 210 9.5 COMPETITIVE MARKET SHARE ANALYSIS 212
INSULIN SYRINGE MARKET10.1 INTRODUCTION 216 10.2 MARKET OVERVIEW 217 10.3 MARKET ANALYSIS AND FORECAST 221 10.3.1 Total Insulin Syringe Market 221 10.3.1.1 Conventional Insulin Syringe Market 224 10.3.1.2 Safety Insulin Syringe Market 227 10.4 DRIVERS AND LIMITERS 230 10.4.1 Market Drivers 230 10.4.2 Market Limiters 230 10.5 COMPETITIVE MARKET SHARE ANALYSIS 234
INSULIN PUMP MARKET11.1 INTRODUCTION 237 11.1.1 Traditional Insulin Pumps 237 11.1.2 Patch Insulin Pumps 237v11.1.3 Simple Insulin Pumps 238 11.2 MARKET OVERVIEW 239 11.3 MARKET ANALYSIS AND FORECAST 243 11.3.1 Total Traditional Insulin Pump Market 243 188.8.131.52 Traditional Insulin Pump Market 247 184.108.40.206 Infusion Set Market 249 220.127.116.11 Pump Reservoir Market 251 11.3.2 Total Patch Insulin Pump Market 253 18.104.22.168 Patch Pump System Market 257 22.214.171.124 Insulin Pod Market 259 11.3.3 Simple Insulin Pump Market 261 11.4 DRIVERS AND LIMITERS 264 11.4.1 Market Drivers 264 11.4.2 Market Limiters 266 11.5 COMPETITIVE MARKET SHARE ANALYSIS 268 ABBREVIATIONS 272
iData’s 9-Step Research MethodologyOur reports follow an in-depth 9-step methodology which focuses on the following research systems:
- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.